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HCV derived from sera of HCV-
infected patients induces pro-
fibrotic effects in human primary 
fibroblasts by activating GLI2
M. Granato1, C. Zompetta2, E. Vescarelli1, C. Rizzello1, A. Cardi1, S. Valia2, G. Antonelli2, 
C. Marchese1, M. R. Torrisi3,4, A. Faggioni1,* & M. Cirone1,*
Hepatitis C virus (HCV) infection is a leading cause of liver fibrosis, especially in developing countries. 
The process is characterized by the excess accumulation of ECM that may lead, over time, to hepatic 
cirrhosis, liver failure and also to hepatocarcinoma. The direct role of HCV in promoting fibroblasts 
trans-differentiation into myofibroblasts, the major fibrogenic cells, has not been fully clarified. In this 
study, we found that HCV derived from HCV-infected patients infected and directly induced the trans-
differentiation of human primary fibroblasts into myofibroblasts, promoting fibrogenesis. This effect 
correlated with the activation of GLI2, one of the targets of Hedgehog signaling pathway previously 
reported to be involved in myofibroblast generation. Moreover, GLI2 activation by HCV correlated with 
a reduction of autophagy in fibroblasts, that may further promoted fibrosis. GLI2 inhibition by Gant 
61 counteracted the pro-fibrotic effects and autophagy inhibition mediated by HCV, suggesting that 
targeting HH/GLI2 pathway might represent a promising strategy to reduce the HCV-induced fibrosis.
Liver fibrosis is a response to chronic liver diseases of different etiologies, including infection by Hepatitis C 
virus (HCV). HCV is a RNA virus, with size of 50 to 80 nm in diameter, belonging to the Flaviviridae family, that 
exists in six different genotypes. It is an important cause of morbidity and mortality worldwide, since it has been 
reported that approximately 170 million of people are infected. HCV-driven liver fibrosis can progress to liver 
cirrhosis and hepatocarcinoma. Despite being a leading cause of morbidity and mortality, effective therapies able 
to reduce liver fibrosis are still lacking. Resident hepatic stellate cells (HSCs) and portal fibroblasts undergoing 
activation and trans-differentiation into myofibroblasts are the major fibrogenic cells1. The direct role of natural 
HCV in inducing pro-fibrotic effects in HSCs and fibroblasts has not been fully clarified. Because of the lack of an 
efficient cell culture system for viral growth and the difficulties to obtain natural HCV, the on-going studies are 
based on JFH1-HCV models. JFH1-HCV subgenomic replicon has been reported to infect embryonic fibroblasts2 
and HSCs3. In addition, it has been recently shown that cell-cultured derived HCV obtained from the Huh7.5 cell 
line infected with the full-length genome of JFH-1 can infect liver myofibroblasts, stimulating their fibrogenic 
activities4.
The Hedgehog (HH) pathway regulates multiple processes involved in development and differentiation of 
tissues and organs during embryonic life5. In humans, three ligands, sonic hedgehog (SHH), desert hedgehog 
(DHH) and indian hedgehog (IHH), are responsible for HH canonical activation, by binding to the inhibitory 
receptor Patched (Ptch). As a consequence of their binding, the repression upon the transmembrane transducer 
Smoothened (Smo) is reduced and the signal is transduced to the downstream GLI transcription factors, namely 
GLI1, GLI2 and GLI35. A non-canonical HH activation, independent of the presence of HH ligands, can also 
occur6. The inappropriate activation of HH pathway has been involved not only in several cancers7,8 but also in 
organ fibrosis9. Moreover, it has been reported that transgenic mice expressing SHH in the liver developed liver 
cirrhosis and were more susceptible to carcinogenesis induced by other oncogenes10. In particular, it has been 
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reported that GLI2, one of the transcription factors activated downstream of HH signaling pathway, induced 
hepatic stellate cells (HSCs) to acquire myofibroblastic phenotype11 and seems to be the more important GLI 
effector in the induction of renal fibrosis12. HH pathway may also regulate autophagy13 and in particular GLI2 
activation negatively influences the autophagic process14.
Autophagy is a catabolic process involved in tissue development and differentiation that also serves to main-
tain normal tissue homeostasis15. Its dysfunction is involved in the pathophysiology of many human disorders, 
including fibrosis. Indeed, autophagy induction may reduce liver fibrosis16 and inhibit HSC proliferation and 
extracellular matrix deposition in mouse models17. Moreover, autophagy induction reduces type I collagen accu-
mulation in HSCs and promotes its degradation, reducing kidney fibrosis18. However, regarding the survival and 
activation of HSCs, the role of autophagy remains still controversial19,20. Interestingly, HH pathway has been 
reported to be up-regulated by HCV and to promote HCV replication in hepatocytes21.
In this study we investigated whether natural HCV, obtained from sera of HCV-infected patients, as previously 
reported22, would infect and directly promote a pro-fibrotic activation in human primary fibroblasts. We also 
asked whether natural HCV would activate GLI2 in human fibroblasts and modulate autophagy in these cells. The 
understanding of the molecular mechanism/s underlying HCV-induced fibrosis is of fundamental importance 
in the attempt to develop new therapeutic strategies to counteract this pathological process, alongside with the 
discovering of more effective therapies aimed at reducing the viral load of HCV23.
Results
HCV derived from sera of HCV-infected patients infects and induces pro-fibrotic effects in 
human primary fibroblasts. Human primary fibroblasts, isolated from skin of healthy donors, were char-
acterized based on their morphology (Fig. 1A), assessment of vimentin (mesenchimal marker) expression by IFA 
(Fig. 1B) and by western blot together with the lack of K19 (epithelial marker) expression (Fig. 1C). The expres-
sion of the putative HCV receptors by these cells was then assessed. We first analysed whether they expressed 
Figure 1. Characterization of human primary skin fibroblasts and HCV receptor expression. Human 
fibroblasts, isolated from skin of healthy donors were analysed (A) by phase contrast optical microscopy to 
assess their morphology (B) by IFA to detect vimentin expression and (C) by western blot analysis to detect the 
expression of vimentin (mesenchymal marker) and the lack of K19 (epithelial marker). (D) The expression of 
the putative HCV receptors CD81, SR-B1 and LDLr was investigated by western blotting using THP-1 cells as 
control.
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CD81 that is considered to be one of the most important among the putative HCV receptors24,25. By western 
blot analysis, we found that this molecule was expressed by primary fibroblasts (Fig. 1D). Then the expression 
of SR-B1, another receptor molecule known to be essential for HCV infection together with CD81 (Kapadia 
S D 2007 j virol) was explored and, as shown in Fig. 1D, SR-B1 was expressed by these cells. Interestingly, we 
found that fibroblasts expressed also LDL receptor (Fig. 1D) which is particularly important, since it is used by 
HCV for the in-vivo infection (Molina S. et al. 2007) given that the virus travels bound to the LDL into the the 
plasma (Burlone M E 2009). As control for the expression of all above reported HCV putative receptors THP1 
cells were used. The western blot results were also confirmed by IFA (data not shown). Next, we investigated 
whether natural HCV, derived from HCV-infected patients with high levels HCV RNA IU/ml of circulating 
HCVRNA, (N2 × 106), would directly infect and induce pro-fibrotic effects in human primary fibroblasts. At this 
aim, these cells were exposed to sera from HCV-infected patients or to HCV-negative patients, as control (20% of 
the final volume). After 4 days of in-vitro culture, the expression of HCV core protein was investigated by western 
blot analysis. The results shown in Fig. 2A indicate that fibroblasts exposed to HCV-containing sera were HCV-
infected, expressing HCV core protein and concomitantly showed a higher expression level of type I collagen, 
the fibrillar collagen mainly produced in the course of fibrosis. Type I collagen production were also evaluated 
by dot blot analysis and accordingly, a higher amount of collagen was found to be released in the supernatants of 
HCV-exposed fibroblasts in comparison with the controls (Fig. 2B). Then, the expression of several markers of 
myofibroblast trans-differentiation such as smooth muscle actin and vimentin was evaluated by western blot anal-
ysis in fibrobasts exposed to HCV-positive or negative sera. The results obtained indicate that fibroblasts exposed 
to HCV-containing sera displayed a higher expression of SMA and vimentin (VIM) (Fig. 2C) in comparison to 
fibroblasts exposed to HCV-negative sera. The increased expression of SMA and type I collagen was then con-
firmed at RNA level by qRT-PCR (Fig. 2D). As control, we treated fibroblasts with TGF beta1 (TGFβ1) (10 ng/ml) 
and found that SMA and collagen type I expression increased in TGFβ1-treated cells in comparison with the 
untreated control (Fig. 2D). Finally, the induction of the fibrotic effects by HCV was investigated by immuno-
fluorescence assay (IFA) and, to confirm that HCV itself was responsible for the induction of the pro-fibrotic 
phenotype, fibroblasts were also exposed to the same HCV-positive sera from which the viral particles were 
removed through ultrafiltration (HCV filtered). A regular culture medium was included as control in addition to 
HCV-negative control sera. We found that fibroblasts exposed to HCV-containing sera showed higher expression 
of type I collagen (Fig. 2E), SMA (Fig. 2F) and vimentin (Fig. 2G) in comparison to fibroblasts exposed to filtered 
HCV sera or HCV-negative sera or control medium, indicating that the natural HCV contained in the sera of 
infected patients was able to infect and directly induce trans-differentiation of human primary fibroblasts into 
myofibroblasts, promoting fibrosis.
HCV derived from sera of HCV-infected patients activates GLI2 in human primary fibro-
blasts. Searching for the molecular pathways underlying the pro-fibrotic activation of fibroblasts, we found 
that GLI2, a target of HH pathway5 was activated and localized mainly in the nuclei of HCV-exposed fibroblasts, 
as evaluated by IFA (Fig. 3A). Then, a western blot analysis performed with a cellular lysate enriched of the 
nuclear fraction, showed a higher GLI2 expression in fibroblasts exposed to HCV-containing sera in comparison 
to the fibroblasts exposed to HCV negative sera (Fig. 3B). To assess the direct role of HCV infection in the acti-
vation of this pathway, we added pegylated interferon alfa plus Ribavirin concomitantly to the HCV-containing 
sera. These drug combination has been reported to be effective in HCV anti-viral therapy26. A reduction of GLI2 
expression was observed in the presence of these antiviral agents (Fig. 3C), indicating that HCV infection plays an 
important role in the mediating this effect. As control, we treated fibroblasts with TGF beta1 and found that, simi-
larly to HCV, it was able to activate GLI2 (Fig. 3D), as previously reported27. This finding suggests that HCV could 
induce the production of TGFβ1 by primary fibroblasts, as it does in other cell types28 and that this could con-
tribute to GLI2 activation together with the effects mediated by the virus itself. GLI2 pathway has been strongly 
linked to fibrogenesis12, and the results obtained in this study suggest that it could play a role in the fibrotic pro-
cess induced by HCV in fibroblasts.
HCV derived from sera of HCV-infected patients reduces autophagy in human primary fibro-
blasts. GLI2 activation has been reported to negatively regulate autophagy14, thus we then asked whether GLI2 
activation by HCV would result in autophagy reduction in human fibroblasts. To this aim, the autophagic marker 
LC3-I/II was analysed by western blot immunoblotting. Since the lipidated form of LC3 (LC3-II) is formed and 
degraded through the autophagic process, we used bafilomycin A1 (baf), which blocks autophagosome-lysosome 
fusion, to evaluate LC3II formation. We found that LC3II expression was reduced in fibroblasts exposed to 
HCV-containing sera in the presence of baf, in comparison to the same cells exposed to HCV-negative control 
sera (Fig. 4A), suggesting that HCV reduces autophagy in fibroblasts. The reduction of autophagy was further 
confirmed by the increase of p62 (Fig. 4B), a protein mainly degraded through autophagy that indeed accumu-
lated in fibroblasts exposed to HCV-containing sera, concomitantly with GLI2 activation (Fig. 4B). We then 
found that GLI2 activation correlated with the reduction of the phosphorylated form of eiF2alfa (Fig. 4C), which 
is essential for autophagy induction29. These results suggest that reduction of eiF2alfa phosphorylation might 
link HCV-mediated GLI2 activation with autophagy inhibition. Since autophagy has been shown to influence 
the fibrotic process by reducing collagen degradation18, it is possible that autophagy inhibition by HCV-mediated 
GLI2 activation could contribute to the pro-fibrotic effects in human primary fibroblasts.
Gant 61 counteracted the pro-fibrotic effects and autophagy inhibition mediated by 
HCV. Next, we investigated whether GLI2 activation would be responsible for the pro-fibrotic effects and 
autophagy inhibition mediated by HCV in primary fibroblasts. At this purpose, fibroblasts were pre-treated 
with Gant 61 (5 μ M), a small molecule able to inhibit GLI230, before exposure to HCV-containing sera. Gant 61 
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pre-treatment, reduced GLI2 activation (Fig. 5A) and resulted in a decrease of type I collagen (Fig. 5B) and SMA 
(Fig. 5C) expression in cells exposed to HCV. Moreover, collagen release was reduced by Gant 61, as assessed by 
Figure 2. HCV induces pro-fibrotic effects in human primary fibroblasts. Human fibroblasts exposed to 
HCV-containing sera or to HCV-negative sera (20% of the final volume, for four days) and (A) HCV core 
protein and Type I collagen expression was investigated by western blot analysis or (B) collagen release was 
investigated by dot blot analysis. (C) SMA and vimentin expression was analysed in fibroblasts exposed to HCV-
positive sera or negative sera. Lamin B or β -Actin were used as loading controls. A representative experiment 
out of 3 is shown. The histograms represent the mean plus SD of the densitometric analysis of the specific 
molecules on loading control of 3 different experiments. (D) SMA (ACTA-2) and collagen type I (COL1A1) 
RNA expression as evaluated by qRT-PCR. mRNA levels were normalized to GAPDH mRNA expression. 
Error bars represent standard deviations. For this experiment, fibroblasts were exposed to HCV-positive and 
HCV-negative sera or as positive control, they were treated for TGFβ1 (10 ng/ml, for four days). Mean plus SD 
of three indepent experiments is shown. Fibroblasts exposed to HCV-positive sera or to the same sera from 
which viral particles removed through ultrafiltration or HCV-negative sera or control medium were analysed 
for the expression of (E) type I collagen (F) SMA and (G) vimentin, by IFA. Blue DAPI staining is also shown. A 
representative experiment out of 3 is shown. Bar: 5 micron.
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dot blot analysis (Fig. 5D). Finally, the impact of Gant 61 on the autophagic process was investigated. As shown 
in Fig. 5E, LC3-II increased in HCV-infected fibroblasts pre-treated with Gant 61 in the presence of baf, in com-
parison to the same HCV-infected untreated fibroblasts, indicating that this small molecule was able to restore 
autophagy in HCV-infected fibroblasts. All together these results suggest that GLI2 activation could be one of the 
mechanisms underlying the fibrogenesis induced by HCV in human primary fibroblasts and that targeting GLI2 
by Gant 61 could be a useful therapeutic strategy to counteract autophagy inhibition and the pro-fibrotic effects 
induced by HCV.
Discussion
Liver fibrosis as well as fibrosis of other organs is a process characterized by the excess accumulation of extra-
cellular matrix (ECM) that is often related to a process of chronic inflammation31. HSCs and portal fibroblasts, 
differentiating into myofibroblasts, are the most important cells involved in the liver fibrosis. HSCs are the 
main fibrogenic cell type in pericentral areas while portal fibroblasts may predominate when liver injury occurs 
around portal tracts. Inflammatory cells that also cross-talk with fibroblasts, also participate to fibrogenesis32. 
HCV chronic infection, autoimmune and biliary diseases and alcoholic steatohepatitis are the leading causes of 
liver fibrosis, process that often progress to hepatic cirrhosis and also to hepatocarcinoma28,33. HCV infection of 
hepatocytes increases production of ROS and transforming growth factor β 1 (TGFβ1) that, in turn, stimulate 
HSCs and portal fibroblasts to become myofibrobasts34. The pathogenesis of HCV-induced liver fibrosis and 
whether the HCV specific proteins play a role in promoting fibrosis is poorly understood, due to the to lack 
of an efficient cell culture system for viral growth and the lack of models of persistent HCV infection. In this 
study, we used natural HCV, derived from sera of HCV-infected patients, to infect human primary fibroblasts 
and investigate the outcome of HCV infection on fibrogenesis. We observed that HCV directly promoted pri-
mary fibroblast trans-differentiation into myofibroblats, based on the increased expression of SMA, vimentin and 
collagen expression/production. We found that these effects were mediated by the virus itself, since its removal 
through ultrafiltration completely abrogates the pro-fibrotic activity of HCV-positive sera. Several HCV proteins, 
including core, have been previously reported to stimulate inflammation and fibrosis in HSCs35. We found that 
fibroblasts exposed to HCV-containing sera expressed HCV core antigen, suggesting that this molecule could 
be involved in the induction of the pro-fibrotic phenotype. Searching for molecular mechanisms underlying 
myofibroblast trans-differentiation, we found that GLI2 was activated in fibroblasts exposed to HCV-containing 
sera in comparison to HCV negative sera. Interestingly, in this study we observed a reduction of GLI2 activation 
Figure 3. HCV activates GLI2 in human primary fibroblasts. (A) GLI2 expression was evaluated in 
fibroblasts exposed to HCV-containing sera or to HCV-negative sera by IFA, Bar: 5 micron or (B) by western 
blot analysis. (C) GLI2 expression was assessed in fibroblasts exposed to HCV-containing sera in the presence 
or in the absence of pegylated interferon and ribavirin or (D) treated with TGF beta 1 (TGFβ 1). β -Actin was 
used as loading control. A representative experiment out of 3 is shown. The histograms represent the mean plus 
SD of the densitometric analysis of the ratio of GLI2 on loading control of 3 different experiments.
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in the presence of pegylated interferon plus Ribaviran anti-viral agents, which confirms that HCV itself plays a 
direct role in maintaining its activation. GLI2 is one of the targets activated downstream of HH pathway signaling 
that has been previously linked to organ fibrosis of several organs such as kidney12 and liver36,37. Its importance 
has been strengthened by the results obtained by the inhibition of GLI2 that led to a reduction of myofibroblast 
generation and of kidney fibrosis38,39. Besides liver fibrosis, the activation of HH pathway has been also linked to 
hepatocarcinoma and its inhibition has been shown to be able to revert both pathological processes in a mouse 
model40. HH pathway plays also a role in the epithelial-mesenchymal transition (EMT) that also promotes fibro-
sis, thus it is emerging as a promising target for the treatment of fibrosis-related diseases9. Of note, HH inhibi-
tion has been shown to reduce fibrosis also in the course of Systemic Sclerosis (SSc)41, whose etiopathology has 
been recently linked to Epstein-Barr virus infection42. The results obtained in this study indicate that Gant 61 
Figure 4. HCV reduces autophagy in human primary fibroblasts. (A) Expression of LC3-I/II in the 
presence or in the absence of Bafilomycin A1 (baf). (B) of p62 and GLI2  and (C) of phospho- and total eIf2α 
in fibroblasts exposed to HCV-containing sera or HCV-negative sera. β -Actin was used as loading controls. A 
representative experiment out of 3 is shown. The histograms represent the mean plus SD of the densitometric 
analysis of the ratio of the specific molecules on loading control of 3 different experiments.
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reduced the pro-fibrotic effects mediated by HCV in primary fibroblasts in terms of SMA and collagen expression 
and production. Interestingly, we found that Gant 61, concomitantly to the reduction of fibrotic markers, also 
counteracted autophagy inhibition induced by HCV. Accordingly, GLI2 activation has been previously reported 
to negatively regulate autophagy13,14 and autophagy inhibition to promote the fibrotic process16. As a possible 
mechanism leading to autophagy inhibition, we have shown that HCV reduced the phosphorylation of eIF2α , a 
mechanism used also by other viruses to interfere with the autophagic process29. It would be interesting, in future 
studies, to explore whether autophagy would be inhibited in fibroblasts by other viruses such as Human Hepatitis 
B (HBV), whose infection has been also strongly linked to liver fibrosis43. Autophagy is often manipulated by 
viruses according to their convenience22,44–46 and HBV, similarly to HCV may induce autophagy to promote its 
replication47. However, autophagy seems to be reduced in HBV-associated tumorigenesis as well as in the tumor 
tissues of HBV-associated hepatocellular carcinomas48,49. Interestingly, HBV can also activate HH pathway to pro-
mote carcinogenesis50. Another virus that promotes the fibrotic process and is involved in the pathogenesis of SSc 
is EBV42 and it will be also important to explore whether GLI2 and autophagy manipulation would be involved in 
mediating the pro-fibrotic effects. In conclusion, the results obtained in this study unveil for the first time a link 
between fibrosis induced by HCV in primary fibroblasts with GLI2 activation and autophagy inhibition. More 
importantly, we found that the treatment with GANT61 was able to counteract all these effects, encouraging the 
use of this small molecule in the reduction of HCV-induced fibrosis. Its use is even more promising when con-
sidering that HH pathway inhibition has been shown also to be able to reduce HCV replication21 that strongly 
correlated with the outcome of HCV-related diseases.
Materials and Methods
Human Sera. Human sera were obtained from healthy donors (HCV, HIV and HBsAg-negative) or from 
HCV-infected patients (HIV and HBsAg-negative), in which the viral load was measured by VERSANT HCV 
RNA 3.0 Assay (Siemens Health Care, Australia). The limits of detection (LOD) and quantification (LOQ) were 
15 HCV RNA IU/ml according to the assay package inserts. Valid results were reported quantitatively (IU/ml), as 
“positive b LOQ” (if the value obtained was under the LOQ), or as “target not detectable”.
Sera from 3 patients, which were anti-IgG HCV positive, as measured by ELISA (ADVIA Centaur, Siemens 
Health Care, Australia) and who had high levels HCV RNA IU/ml of circulating HCVRNA, (N2 × 106), genotype 
1, were used throughout the study.
In some experiments, the HCV-positive sera were ultrafiltered with 30 k Vivaspin columns (Sartorius, 
Goettingen, Germany, Europe). This ultrafiltration process, validated for removal of a variety of enveloped and 
non-enveloped viruses with size from 70 nm to 30 nm, was used to remove HCV particles.
Cell culture and reagents. Primary cultures of human fibroblasts (HF) were established from 1 cm2 skin 
biopsy from healthy donor. Dermis was excised from the biopsy sample and subjected to enzymatic dissociation 
for 20 min at 37 °C. Then cells were seeded onto collagen IV (10 mg/mL) coated culture plates and maintained in 
Dulbecco’s modified Eagle medium (DMEM) (Sigma, St. Louis, MO, USA; D6546), supplemented with 10% Fetal 
Figure 5. Gant 61 counteracts the pro-fibrotic effects and autophagy inhibition induced by HCV. (A) GLI2, 
(B) type I collagen and (C) SMA expression in HCV-exposed fibroblasts pre-treated or not with GANT61 
61 (5 μ M). Lamin B or β -Actin were used as loading controls. (D) Dot-blot analysis showing type I collagen 
release in the culture conditioned medium of fibroblasts pre-treated or not with Gant 61 and exposed to HCV-
containing sera. (E) Expression of LC3-I/II in the presence or in the absence of bafilomycin in fibroblasts pre-
treated or not with Gant 61 and exposed to HCV-containing sera. β -Actin was used as loading control and a 
representative experiment out of 3 is shown. The histograms represent the mean plus SD of the densitometric 
analysis of the ratio of specific molecules on loading control of 3 different experiments.
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Bovine Serum (FBS) (Euroclone, Milan, Italy; ECLS0180L), L-glutamine (100 μ g/ml) (Aurogene, Rome, Italy; 
AU-X0550-100) and streptomycin/penicillin (100 U/ml) (Aurogene, Rome, Italy; AU-L0022-100) in 5% CO2 at 
37 °C, with medium change twice a week.
To better characterize HF cell cultures, we examined their morphology by phase contrast microscopy. 
Furthermore, to better clarify HF mesenchymal origin, we performed immunofluorescence analysis to evaluate 
vimentin expression. The expression of a specific mesenchymal marker (vimentin) and the lack of expression of 
an epithelial marker (K19), were also assessed by western blot analysis, confirming HFs mesenchymal origin. 
Fibroblasts characterization is shown in Fig. 1A–C.
Human Fibroblasts were grown in culture-dishes (∅ 60 mm) (SPL Lifescience Inc., Korea) in 3 ml or cultured 
on coverslips (∅ 12 mm) (Carl Roth GmbH + Ko.KG, Karlsruhe, Germany) in 1 ml of DMEM.
THP-1 cells were purchased from ATCC (USA).
To investigate autophagy, in some experiments, fibroblasts were treated with Bafilomycin A1 (20 nM) (Santa 
Cruz Biotechnology Inc., Europe), an inhibitor of vacuolar-H+-ATPase, for the last three hours.
As HCV antiviral agent, a combination of Pegylated Interferon alfa (100 U/ml) and Ribavirin (50 ug/ml), both 
purchased from Roche (Italy), was used.
TGFβ1, purchased from Sigma Aldrich (Italy) was used at 10 ng/ml to treat fibroblasts, for 4 days.
GANT 61 (5 μ M) (Enzo Life Science, Lausen, Switzerland) was used as chemical inhibitor of GLI proteins, as 
previously described51.
HCV infection and treatments of Human Fibroblasts. HCV infection was performed by exposing 
HF to HCV-positive or HCV-positive filtered sera or HCV-negative for 60 minutes at 37 °C. Cells were then 
cultured for 4 days in a medium containing 20% of the same sera or control medium in 1.5 ml (dishes) or 0.5 ml 
(coverslips).
In same experiments Pegylated Interferon alfa and Ribavirin (used at 100 U/ml and 50 ug/ml, respectively) 
were added concomitantly to HCV-positive sera.
To inhibit the Hedgehog pathway, HF were pre-treated with GANT61 (5 μ M) for 30 min and then exposed to 
the HCV-positive sera.
Antibodies. In this work we used the following primary antibodies:
Mouse monoclonal anti-Vimentin (1:100) (Dako, Glostrup, Denmark), mouse monoclonal anti-Smooth 
Muscle Actin15 (1:100) (Dako, Glostrup, Denmark), rabbit polyclonal anti-Collagen Type 1 (1:1500) (Novus 
Biologicals, Cambridge, UK), mouse monoclonal anti-K19 (Santa Cruz, Biotechnology Inc., Europe), rabbit pol-
yclonal anti-GLI2 (1:100) (Santa Cruz Biotechnology Inc., Europe), rabbit polyclonal anti-peIF2α (1:200) (Cell 
Signaling, Europe) and rabbit polyclonal anti-eIF2α (1:500) (Cell Signaling, Europe). Anti CD81, anti-SR-B1 
and anti-LDL recetor were purchased by Novus Biologicals, Cambridge, UK and used 1:100. The HCV infec-
tion was controlled using a rabbit polyclonal anti-Hepatitis C Virus Core Antigen (HCV Core) (1:100) (Abcam, 
Cambridge, UK) antibody. To study autophagy, we used the following primary antibodies: rabbit polyclonal 
anti-LC3 (1:1000) (Novus Biologicals, Cambridge, UK), mouse monoclonal anti-p62 (1:1000) (BD Transduction 
Laboratories, San Jose, CA, USA).
Monoclonal mouse anti-α -Tubulin (1:1000), (Sigma Aldrich, Europe), anti-β -Actin (1:10000) (Sigma Aldrich, 
Europe), and goat polyclonal anti-Lamin B (1:100) (Santa Cruz Biotechnology Inc., Europe) were used as load-
ing controls. The monoclonal anti-mouse IgG-HRP (Santa Cruz Biotechnology Inc., Europe), the polyclonal 
anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc., Europe) and the polyclonal anti-goat IgG-HRP (Santa Cruz 
Biotechnology Inc., Europe) were used as secondary antibodies in western blot analysis. All the primary and sec-
ondary antibodies were diluted in PBS-0.1% Tween20 solution containing 3% of BSA.
Western blot analyses. 1.5 × 106 HF were washed twice with 1X PBS solution and centrifuged at 1500 rpm 
for 5 minutes at 4 °C. The cells were lysed in a 1X RIPA buffer containing 150 mM NaCl, 1% NP-40, 50 mM 
Tris-HCl (pH8), 0.5% deoxycholic acid, 0.1% SDS, protease and phosphatase inhibitors. Then, the lysates were 
incubated on ice for 20 min and centrifuged at 14000 rpm for 20 min at 4 °C. The first supernatant (labeled as I) 
was separated from the remaining pellet (including cellular debris and also the insoluble fraction containing 
the nuclear matrix). Subsequently, 50 μ l of 1X RIPA plus 0.1% Triton X-100, was added to the pellet that it, kept 
on ice, was sonicated for 45 seconds at the power of 180 watts (in round of 10 seconds). Then, the samples were 
centrifuged as described before and the second supernatant (labeled as II) were mixed to the first one (I). 30 μ g 
of protein lysates were subjected to electrophoresis on 4–12% NuPage Bis-Tris (Life Technologies, Carlsbad, CA, 
USA) or 3–8% (GLI2 protein) NuPage Tris-Acetate gels (Life Technologies, Carlsbad, CA, USA), according to 
the manufacturer’s instruction. To evaluate the LC3-I/II, the cell lysates were denatured in 3X Loading Protein 
Buffer (150 mM Tris (pH 6.8), 6% SDS, 30% Glycerol, 30 mM EDTA, 0.2% Bromophenol Blue) for 5 min at 
100 °C and run on 15% gel (30% acrylamide/Bis Solution 29:1) (Biorad, Hercules, CA, USA) in Tris-Glycine-SDS 
buffer. Then, the gels were transferred to Nitrocellulose Membranes (Biorad, Hercules, CA, USA) for 2 hrs in 
Tris-Glycine buffer. The membranes were blocked in PBS 0.1% Tween20 solution containing 3% of BSA, probed 
with specific primary and secondary antibodies. Finally, bands on membranes were revealed using an ECL 
Blotting Substrate (Advansta, Menlo Park, CA, USA).
Dot Blot. Supernatants recovered from HF cultured in DMEM medium in the presence of HCV-negative and 
HCV-positive with or without GANT61 (5 μ M) (Enzo Life Science, Lausen, Switzerland) were used to perform a 
dot blot assay to detect the release of Collagen Type I. Briefly, the supernatants were diluted in 1X PBS at different 
concentrations (1:10; 1:50; 1:100). Then, 3 μ l of samples were spotted on a rectangular nitrocellulose membrane 
and allowed to dry for some minutes. The membranes were blocked in PBS 0.1% Tween20 solution containing 
www.nature.com/scientificreports/
9Scientific RepoRts | 6:30649 | DOI: 10.1038/srep30649
5% of BSA for 1 hour and then were incubated with a rabbit polyclonal anti-Collagen Type 1 (1:1500) (Novus 
Biologicals, Cambridge, UK) antibody for 1 hour at room temperature. An anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology Inc., Europe) was used as secondary antibody for 30 min at room temperature. All the primary and 
secondary antibodies were diluted in PBS-0.1% Tween20 solution containing 3% of BSA. Finally, a chemilumi-
nescence kit, ECL Blotting Substrate (Advansta, Menlo Park, CA, USA), was used to detect signals.
Quantitative Real-Time PCR. Cells were processed for total RNA extraction with the use of TRIzol reagent 
(Invitrogen, Karlsruhe, Germany). cDNA was generated with oligo (dT) from 1 μ g of RNA using the SuperScript 
III Reverse Transcriptase Kit (Invitrogen). For ACTA-2 and Collagen-1 mRNA detection, commercially available 
specific probes were used (Applied Biosystems by Life Technologies, Carlsbad, CA, USA) (COL1A1,4331182; 
Applied Biosystems by Life Technologies, Carlsbad, CA, USA) (ACTA2, 4331182; Applied Biosystems by Life 
Technologies, Carlsbad, CA, USA). A total of 2 μ l/well of template was added to the sample wells along with 
Taqman Universal PCR master mix at a concentration of 1x and water to a volume of 25 μ l/well. Assays were per-
formed in triplicate on an ABI 7500 Real-Time instrument (Applied Biosystems) using the following conditions: 
50 °C for 2 minutes, 95 °C for 10 minutes, and then 95 °C for 15 seconds and 60 °C for 1 minute, repeated 40 times. 
Relative quantification was performed using GAPDH mRNA as an endogenous control: for each examined sam-
ple, ACTA-2 and Collagen-1 mRNA expression data were normalized to the GAPDH expression.
Indirect Immunofluorescence assay (IFA). The human fibroblasts were seeded on coverslips in 24-wells 
plates, exposed or not exposed to HCV-positive filtered or not filtered or negative sera and grown in DMEM 
medium containing the same sera (20% of the final volume) for 4 days before immunofluorescence (IFA). In 
same experiments, fibroblasts were pre-treated with GANT61 (5 μ M) before exposing to the HCV-positive sera. 
IFA was performed as described previously52. Briefly, HF-cultured on coverslips were washed three times in 
1X PBS and then fixed in 2% paraformaldehyde diluted in 1X PBS for 30 min at 25 °C. The cells were perme-
abilized with a 0.1% Triton X-100 solution for 5 min. After several washing with 1X PBS, HF were incubated 
with the following primary antibodies: mouse monoclonal anti-Vimentin (1:100 in 1X PBS) (Dako, Glostrup, 
Denmark), mouse monoclonal anti-Smooth Muscle Actin (1:100 in 1X PBS) (Dako, Glostrup, Denmark) 
and rabbit polyclonal anti-GLI-2 (1:100 in 1X PBS) (Santa Cruz Biotechnology Inc., Europe). Subsequently, 
they were washed three times in 1X PBS and incubated with polyclonal Cy3-conjugated or FITC-conjugated 
sheep-anti mouse (1:1000 in 1X PBS) or Rhodamine (TRITC) Goat anti-Rabbit (1:300 in 1X PBS) (Jackson 
Immunoresearch Laboratories, West Grove, PA, USA) for 30 minutes at room temperature. Nuclei were stained 
with 4′ ,6′ -diamino-2-phenylindole (DAPI) for 1 min at room temperature. Finally, cells were resuspended in a 1X 
PBS-glycerol solution (1:1) and the immunofluorescence was analyzed by using an Apotome Axio Observer Z1 
inverted microscope, equipped with an AxioCam MRM Rev.3 at 40× magnification.
Densitometric Analysis. The quantification of proteins bands was performed by densitometric analysis 
using the Image J software, which it was downloaded from NIH web site (http://imagej.nih.gov).
Ethics statement. The study was approved by the ethical Committee of “Policlinico Umberto I”.
The experiments were carried out in accordance with the approved guidelines and the “informed” consent was 
obtained from all subjects.
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